Vident Advisory LLC Has $20.93 Million Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Vident Advisory LLC's stake in Edwards Lifesciences Corporation decreased by 2.3% to 288,720 shares, valued at approximately $20.93 million at the end of the first quarter.
• Several institutional investors, including Jennison Associates LLC and Brown Advisory Inc., significantly increased their holdings in Edwards Lifesciences during the first quarter.
• Edwards Lifesciences reported a quarterly earnings per share (EPS) of $0.67, exceeding analysts' expectations, and announced set guidance for future EPS between $0.540-$0.600 for Q3 2025.

Vident Advisory LLC decreased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 2.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 288,720 shares of the medical research company's stock after selling 6,663 shares during the period. Vident Advisory LLC's holdings in Edwards Lifesciences were worth $20,926,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. lifted its stake in Edwards Lifesciences by 1.6% in the first quarter. GKV Capital Management Co. Inc. now owns 12,495 shares of the medical research company's stock valued at $906,000 after acquiring an additional 200 shares during the last quarter. State of Wyoming boosted its stake in Edwards Lifesciences by 38.3% during the first quarter. State of Wyoming now owns 2,676 shares of the medical research company's stock worth $194,000 after buying an additional 741 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at $2,472,000. BNP Paribas Financial Markets lifted its position in Edwards Lifesciences by 37.0% during the 1st quarter. BNP Paribas Financial Markets now owns 1,946,818 shares of the medical research company's stock worth $141,105,000 after buying an additional 525,822 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. AG lifted its position in Edwards Lifesciences by 3.9% during the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 66,107 shares of the medical research company's stock worth $4,791,000 after buying an additional 2,461 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 1.7%

Shares of EW stock traded down $1.37 during mid-day trading on Wednesday, reaching $80.40. 951,969 shares of the stock traded hands, compared to its average volume of 4,467,175. The stock's fifty day simple moving average is $78.55 and its two-hundred day simple moving average is $75.10. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The company has a market cap of $47.20 billion, a price-to-earnings ratio of 11.56, a price-to-earnings-growth ratio of 3.92 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the firm posted $0.70 earnings per share. The business's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of recent analyst reports. Truist Financial upped their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Mizuho upped their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Deutsche Bank Aktiengesellschaft increased their price objective on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. Finally, Citigroup restated a "buy" rating and issued a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $85.90.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,014 shares of company stock worth $1,698,844 over the last three months. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.